Skin Disorders News

Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating the efficacy of the ointment’s 2% formulation, the company announced in a press release.

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 weeks of treatment, with responses as early as week 1, according to an online presentation by Jasper Therapeutics.

Allergy and immunology lost a pioneer last summer with the death of Marcus Maurer, MD, executive director of the Institute of Allergology at Charité University Medicine, Berlin.

Severe disease, male sex, family history and prenatal factors were significantly associated with an increased risk for atopic march progression in infants with atopic dermatitis, according to a study.

The year 2024 was important for skin disorders with many innovations and breakthroughs.

The popular atopic dermatitis drug dupilumab has been found to be associated with an increased risk for cutaneous T-cell lymphoma in treated patients. It was the top dermatitis article in dermatology this year.

BOSTON — Chronic hand eczema can interfere with daily activities and have a significant negative impact on quality of life, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Patients who used dupilumab for atopic dermatitis had significantly lower risks for internal malignancies than patients using other therapies, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.